½ðÄê»á¡¤(jinnianhui)½ð×ÖÕÐÅÆ³ÏÐÅÖÁÉÏ-Gold Annual Meeting

  • »¶Ó­À´µ½ÉϺ£Í¨Îµ£¡

    021-54845833/15800441009

    Æ·Öʱ£Ö¤ ¡¤ ͨεÊÔ¼Á

    µ±Ç°Î»ÖÃ: Ê×Ò³ > ¿ÆÑвúÆ· > ¿ÆÑп¹Ìå > Ò»¿¹ > Íÿ¹CNTD2¶à¿Ë¡¿¹Ìå

    ²úÆ·ÖÐÐÄ

    ×îвúÆ·

    • Íÿ¹CNTD2¶à¿Ë¡¿¹Ìå

      ¹æ¸ñ£º
      ¼Û¸ñ£º£¤
      • Æ·ÅÆ : ͨεÉúÎï
      • Ŀ¼ºÅ : TW15120
      • Ó¦Óà : ½ö¹©¿ÆÑÐʹÓÃ
      • »õÆÚ : ÏÖ»õ
      • ¹æ¸ñ £º100ul/200ul/25ul
    • ÉÌÆ·ÏêÇé
    • ²Î¿¼ÎÄÏ×
    • ˵Ã÷ÊéÏÂÔØ
    • ÉÌÆ·ÆÀÂÛ0
    • Ïà¹Ø²úÆ·


    ÖÐÎÄÃû³Æ£º
    Íÿ¹CNTD2¶à¿Ë¡¿¹Ìå


    Ó¢ÎÄÃû³Æ£ºAnti-CNTD2 rabbit polyclonal antibody

    ±ð      Ãû£ºCCNP

    ¿¹      Ô­£ºCNTD2

    ´¢      ´æ£ºÀä¶³£¨-20¡æ£© ±Ü¹â

    ËÞ      Ö÷£ºRabbit

    ·´Ó¦ÖÖÊô£ºHuman

    Ïà¹ØÀà±ð£ºÒ»¿¹

    ±ê  ¼Ç ÎUnconjugate

    ¿Ë¡ÀàÐÍ£ºUnconjugate

    ¼¼Êõ¹æ¸ñ

    Background:

    2 isoforms of the human protein are produced by alternative splicing.

    Applications:

    IHC

    Name of antibody:

    CNTD2

    Immunogen:

    Synthesized peptide derived from internal of human CNTD2.

    Full name:

    cyclin N-terminal domain containing 2

    Synonyms£º

    CCNP

    SwissProt:

    Q9H8S5

    IHC positive control:

    Human breast carcinoma tissue

    IHC Recommend dilution:

    50-100




    ¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿
    ¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿